Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Jennerex Phase 2 JX-594 clinical data for hepatocellular carcinoma presented at ILCA meeting

Jennerex Phase 2 JX-594 clinical data for hepatocellular carcinoma presented at ILCA meeting

Addition of sorafenib to chemotherapy does not prolong survival

Addition of sorafenib to chemotherapy does not prolong survival

Sorafenib could be effective against multiple myeloma

Sorafenib could be effective against multiple myeloma

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Jennerex initiates JX-594 Phase 2 trial in advanced hepatocellular carcinoma

Jennerex initiates JX-594 Phase 2 trial in advanced hepatocellular carcinoma

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bristol-Myers Squibb reports results from brivanib plus sorafenib phase III trial on HCC

Bristol-Myers Squibb reports results from brivanib plus sorafenib phase III trial on HCC

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

Jennerex announces data from JX-594 clinical studies on cancer

Jennerex announces data from JX-594 clinical studies on cancer

Exelixis reports positive interim data from cabozantinib phase 2 trial on HCC

Exelixis reports positive interim data from cabozantinib phase 2 trial on HCC

New evidence of important role of next-generation sequencing in cancer treatment

New evidence of important role of next-generation sequencing in cancer treatment

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Scientists may be step closer to developing new therapy for AML

Scientists may be step closer to developing new therapy for AML

Bayer’s Nexavar Phase 3 trial on NSCLC does not meet primary endpoint

Bayer’s Nexavar Phase 3 trial on NSCLC does not meet primary endpoint

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

Data from Jennerex JX-594 clinical trials on cancer to be presented at ASCO annual meeting

Data from Jennerex JX-594 clinical trials on cancer to be presented at ASCO annual meeting

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC